HAYA Therapeutics: $65 Million Series A Closed To Deliver Precision RNA-Guided Medicines
By Amit Chowdhry ● May 8, 2025
HAYA Therapeutics - a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases - announced that the company has raised $65 million in Series A funding. The funding round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company (Lilly), ATHOS, +ND Capital, Alexandria Venture Investments, and LifeLink Ventures, with additional support from existing investors Apollo Health Ventures, Longview Ventures (an affiliate of Broadview Ventures), 4see ventures, BERNINA Bioinves,t and Schroders Capital.